Table 1.

Patient demographics.

CharacteristicNn (%)
Female40843114 (76.25)
White40843310 (81.05)
Age at disease onset ≥ 65 yrs4083587 (14.38)
Rheumatoid factor-positive37792957 (78.25)
Comorbid asthma or COPD4084455 (11.14)
Extraarticular manifestations (classified as associated with RA*)4084907 (22.21)
Ischemic heart disease4084171 (4.19)
Comorbid conditions classified as not associated with RA4084196 (4.80)
Prednisone use40842306 (56.46)
Biologic DMARD40841585 (38.81)
Nonbiologic DMARD classified as posing a significant infection risk40843281 (80.34)
Nonbiologic DMARD classified as not posing a significant infection risk40841488 (36.43)
Received > 10 mg/day oral prednisone or equivalent4084975 (23.87)
  • * Fever, Felty syndrome, vasculitis, Sjögren syndrome, interstitial lung disease, bronchiolitis, pleural effusion or thickening, pulmonary fibrosis, pulmonary nodules, ulcers, rash, nodules, uveitis, iritis, scleritis, episcleritis, keratoconjunctivitis sicca, Raynaud syndrome, and pericarditis.

  • Chronic liver disease, congestive heart failure, ischemic heart disease, renal disease, and deep vein thrombosis. COPD: chronic obstructive pulmonary disease; DMARD: disease-modifying antirheumatic drug; RA: rheumatoid arthritis.